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INTRODUCTION
Osteoporosis is a global health problem that affects more than 75 million people in the
United States, Europe, and Japan. Between the United States and Europe, more than 2.3 million
people sustain fractures annually due to osteoporosis.1
Osteoporosis is a chronic condition characterized by decreased bone mass and deterioration
of bone microarchitecture both of which compromise bone strength, predisposing people to
fragility fracture.2 The World Health Organization (WHO) defines severe osteoporosis
(established osteoporosis) as a bone mineral density (BMD) 2.5 standard deviations or more below
the young adult mean accompanied by one or more fragility fractures. Osteoporosis is more
common in women than men, due to women’s lower peak bone mass and their declining estrogen
levels with age. Peak bone mass occurs around 30 years. Estrogen helps preserve bone mass, but
its levels decrease after menopause. As these hormonal levels decrease, bone mass declines and
bone weaken, resulting in fractures that often occur with a fall. Many people become bedridden
after a fracture which causes secondary complications that can be life-threatening.1,3
For those at risk, or for those already diagnosed with osteoporosis, prevention and
treatment generally include increasing activities such as weight-bearing exercises, increasing
calcium intake, making lifestyle changes and quitting tobacco. These measures often help prevent
further bone loss even when pharmacological therapy is started.
Pharmacological intervention for osteoporosis requires continuous treatment with
medications that primarily act on the bone resorption component of bone remodeling pathways.
Among currently available agents, oral bisphosphonates and subcutaneous injection denosumab
are commonly prescribed for osteoporosis.3 Of the two medications, oral bisphosphonates are
considered the first line of treatment. Oral bisphosphonates are traditional antiresorptive agents
that contain nitrogen and potently inhibit osteoclast-mediated bone resorption.4,5 Denosumab is a
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subcutaneous (SC) injection given in the amount of 60mg every six months. It is a fully human
monoclonal antibody (immunoglobulin G subclass 2 [IgG2]) with high affinity and specificity for
human receptor activator of NF-kB ligand (RANKL). It neutralizes the activity of human RANKL,
similar to the action of endogenous osteoprotegerin. Denosumab blocks RANKL, inhibits
osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing
bone mass and strength in both trabecular and cortical bone.3
For postmenopausal women with osteoporosis, initiating treatment is vital to increasing
bone mineral density and avoiding bone fragility, which can lead to fractures. Long-term treatment
of osteoporosis in postmenopausal women with bisphosphonates increases bone mineral density.
Even though oral bisphosphonates are the most commonly prescribed medication for osteoporosis,
a majority of postmenopausal women discontinue bisphosphonate therapy within the first year of
treatment due to cost, dose schedules, and side effects, thus, causing poor drug adherence.
Evaluation of pharmaceutical treatments for newly diagnosed osteoporosis in postmenopausal
women requires comparison of oral bisphosphonates to denosumab in order to assess which
pharmacological treatment is better for preventing bone loss or fractures, with the least side effects,
and the best overall compliance of treatment within the first few years of treatment.

DISCUSSION
Although postmenopausal women with osteoporosis are usually started on first linetreatment with bisphosphonates, studies show that bone mineral density can also improve with
denosumab. Therefore, comparisons of bone mineral density, patient compliance, and medication
adherence between bisphosphonates and denosumab were examined. Eleven articles about drug
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treatment of postmenopausal women with osteoporosis were found that had sufficient good quality
evidence, including some direct comparisons of oral bisphosphonates to denosumab.
Current Evidence
Individual Agents
Bisphosphonates—Oral risedronate was compared to intravenous (IV) ibandronate with
the MOVER study. Those patients receiving IV ibandronate achieved significantly higher
responder rates than those receiving oral risedronate at all bone sites. The advantage of the study
showed that both ibandronate and risedronate helped increase BMD over three years. However,
ibandronate was administered by IV route, which made bioavailability 100% versus the oral route
of risedronate. Due to administration of the drugs, the outcome shows a greater BMD gain with
ibandronate. The study did not examine the overall compliance, adherence, or side effects of oral
risedronate, which factors could have resulted in lower BMD compared to ibandronate.4
Denosumab—The FREEDOM trial included participants who received 2-5 previous doses
of denosumab or placebo and had stopped taking either agent. Fracture incidence was then
measured at 7 months or longer after stopping these agents. Both groups sustained an osteoporosisrelated fracture during the follow-up period. Many placebo-treated subjects initiated other
osteoporosis therapies, specifically a bisphosphonate, during the off-treatment period, which
would have been expected to lower their fracture rate. Interestingly, the fracture incidence in the
placebo group remained higher compared with the denosumab group. Fracture data during the offtreatment period may have been more difficult to obtain due to the ethics of discontinuing
osteoporosis treatment in an individual at increased risk for fracture.12
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Another study focused on denosumab alone to evaluate medication-taking behavior of
1500 postmenopausal women from Germany, Austria, Greece, and Belgium receiving denosumab.
Persistence with adherence to osteoporosis therapy is an important factor in achieving successful
treatment outcomes, particularly for fracture reduction. After 12 months, results showed that
persistence with denosumab at 12 months was consistently high in all four countries. The
persistence observed in the study was at least 1.5-10-fold higher than the persistence found with
bisphosphonates in 12-month studies. This study was limited by the different reimbursement for
these drugs that the patients received in different countries. In Austria and Germany, participants
were fully reimbursed, in Greece patient pay 10-25% of costs, and in Belgium patients pay 1627% and no overall analyses were performed.9

Comparison Studies—Bisphosphonates to Denosumab
A meta-analysis of 11 studies with head-to-head comparisons of 2873 participants on
denosumab and 2573 on bisphosphonates suggested that denosumab significantly increased BMD
at the hip, femoral neck, lumbar spine, and one-third radius. No significant difference in fracture
risk was found between denosumab compared to bisphosphonates. Furthermore, no significant
difference between denosumab and bisphosphonates was found for adverse events or withdrawal
due to adverse events. The meta-analysis did not report whether the bisphosphonates were taken
daily or weekly. These studies were sponsored by pharmaceutical companies, resulting in potential
publication bias.11
The DAPS included 221 participants open-label study, over a two-year period, that
compared adherence of denosumab to oral alendronate once weekly. After one year, more subjects
were nonadherent to alendronate compared to denosumab. A total of 198 subjects expressed a
preference in treatment of denosumab compared to alendronate tablets and 91.2% chose
5

denosumab for long-term treatment. Postmenopausal women who received denosumab every six
months had significantly better adherence, compliance, and persistence than women who selfadminister alendronate orally once weekly. The administration route for denosumab required
subcutaneous administration by healthcare professionals with direct evidence of patient adherence
to treatment. Follow-up visits with bisphosphonate treatment typically occur annually, however,
visits in the study occurred every six months, which could have enhanced adherence. Also,
adherence of weekly alendronate treatment required subjects to take at least 80% of the tablets,
include two of four doses in the final month, in contrast, denosumab adherence which required
administration of 100% of the doses, possibly biasing against denosumab adherence.5
An additional study included 875 postmenopausal women were randomized to receive
denosumab or oral risedronate. The participants were previously adherent to alendronate therapy
and the study focused on transitioning participants to SC denosumab or oral risedronate. After one
year, those who transitioned to denosumab, showed an increase of BMD at the total hip compared
to those participants on risedronate. Adverse effects occurred in both the risedronate group and the
denosumab group, side effects included; hypertension, arthralgia, nasopharyngitis, constipation.
The incidence of clinical fractures was similar between the two groups, 17 in the risedronate group
and 23 subjects in the denosumab group. Of the fractures acquired throughout the study, 10
subjects from the risedronate group and 6 subjects in the denosumab group had a medical history
of osteoporotic fractures at baseline. The study was not designed with adequate statistical power
to evaluate anti-fracture efficacy of denosumab and risedronate. Many of the subjects who
sustained a fracture on-study had a history of fractures at study entry, that may have increased their
risk for future fractures.6
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Adhering to treatment of osteoporosis for postmenopausal women can be challenging.
Higher treatment satisfaction was associated with greater persistence with therapy, which was
associated with better outcomes. Pooled data of 1703 postmenopausal women from two
international multicenter, randomized, open-label study evaluated patients transitioned from oral
daily or weekly bisphosphonates to either denosumab or monthly oral bisphosphonates. At 6 and
12 months, patients in both treatment groups showed improvement from baseline for all four
domains of treatment satisfaction but the satisfaction was greater for denosumab than for
alendronate. Those with lower satisfaction with osteoporosis treatment were more likely to
discontinue/switch medications than women who reported higher satisfaction.8 Low adherence to
long-term therapies result in diminished health benefits and increased health costs. In patients with
osteoporosis, nonadherence to medication is associated with increased risk of fracture as compared
with those who are adherent.
The DAPS study which included 250 postmenopausal women, compared adherence to
subcutaneous denosumab 60mg every 6 months or oral alendronate 70mg once weekly. After year
one and two, adherence to denosumab was greater than treatment adherence to alendronate.
Adherence rates were higher-than-expected due to participants knowing they were being
monitored for adherence during the trial. Also, participants were evaluated by osteoporosis experts
at referral centers which may not represent real-world clinical practice for either alendronate or
denosumab users.7
To evaluate bone mineral density and bone metabolism, a total of 113 postmenopausal
women were randomized to receive denosumab or alendronate 70mg once weekly along with
vitamin D. After 12 months, BMD increases in the denosumab group were greater than those found
in the bisphosphonate group. No changes in serum calcium were observed in either the denosumab
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or alendronate group. Limitations of the study included a small sample size. Furthermore, the
observational design may have introduced unintentional bias. The baseline characteristics were
identical between the two study groups, which was a strength.3
Another study provided further evidence that denosumab was superior to bisphosphonates.
Four hundred, twenty-five postmenopausal women with osteoporosis completed a trial of
denosumab that examined BMD and bone turnover markers. Additionally, the effect of denosumab
in bisphosphonate-naïve patients was compared to its effects on patients previously treated with
bisphosphonates. Those patients whose densitometric gain was over 3% after one year of
denosumab treatment were considered responders. Denosumab increased BMD in both
bisphosphonate-prior and bisphosphonate-naïve women. Limitations of this study included a
lower number of bisphosphonate-naïve women participating compared to the number of
bisphosphonate-prior women. BMD was recorded after one year of treatment without intermediate
measurements. BMD measurements were not completed by the same examiner. Most of the
women in the bisphosphonate group were switched to denosumab because of poor clinical
response to bisphosphonates which imposed bias.2
Lastly, an observational study with 78 postmenopausal osteoporotic women examined the
effects of switching from daily teriparatide to either oral bisphosphonates or denosumab. After one
year, no significant difference was observed between the groups in baseline age, body mass index,
rate of prior vertebral fracture, overall BMD, or bone turnover markers. However, although both
denosumab and bisphosphonates increased lumbar spine and total hip BMD, bisphosphonates did
not increase femoral neck BMD whereas denosumab did. Limitations included small sample size.
In addition, oral intake of calcium was not assessed, which may have affected the results.10
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Efficacy
Bone mineral density was an important marker to measure when comparing
bisphosphonates to denosumab. Many of the studies completed baseline readings at three skeletal
sites; lumbar spine, femoral neck, and total hip. Numerous results showed greater improvement of
bone mineral density with denosumab subcutaneously every six months compared to those on
bisphosphonates. Bone mineral density and bone turnover are not the only predictors for risk of
fracture, but BMD is important to consider when managing and monitoring osteoporosis. In
addition, numerous studies incorporated oral calcium supplementation during the treatment period
and the oral calcium was not assessed, which may have affected the results.

Safety
Adverse events where monitored while participants took either bisphosphonates or
denosumab. The most frequently experienced adverse events were hypertension, arthralgia,
nasopharyngitis, constipation, extremity pain, and back pain. Most of the adverse events in both
bisphosphonate and denosumab groups were categorized as being either mild or moderate in
severity. Serious adverse events reported with denosumab were osteoarthritis, radius fracture,
pubic fracture, cerebral ischemia, cerebrovascular accident, and atrial fibrillation. The serious
adverse events reported with bisphosphonates included fibular fracture, breast cancer, and
coronary artery stenosis.5,6

Persistence to Therapy
Patient compliance and adherence were higher with denosumab than bisphosphonates. The
dosing intervals of SC denosumab every six months was preferred among most groups. Due to
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daily or weekly dosing schedules for oral bisphosphonates, a high rate of frequently missed or
incorrectly-timed doses occurred, resulting in poor medication compliance, adherence and
persistence. Those who were treatment-naïve or whose dosing schedules of bisphosphonates were
difficult to follow were most likely to take their medication consistently.

SUMMARY
The purpose of the analysis was to evaluate first-line treatment of bisphosphonates
compared to denosumab for postmenopausal women with osteoporosis by comparing the bone
mineral density, side effects, and overall compliance. Bisphosphonates are currently the most
commonly used treatment for osteoporosis and are prescribed as a first-line therapy. Dosing often
requires daily, weekly, or monthly doses. Denosumab is a subcutaneous injection that is more
efficacious than bisphosphonates and is a long-acting injectable over a six-month period before
the next dose. The bone mineral density was compared between the two pharmacological
treatments. Bone mineral density increased with either bisphosphonates or denosumab. Many
findings showed that denosumab increased bone mineral density more than oral bisphosphonates.
Furthermore, no studies were done that examined fracture prevention as an outcome either oral
bisphosphonates or denosumab.
Compliance with pharmacologic treatment for osteoporosis is vital. Poor adherence to
therapy, difficult dosing regiments, and multiple side effects may limit drug adherence. Poor
adherence to therapy is common and is associated with unfavorable outcomes. In addition, if a
patient with poor compliance incurs a low-trauma fracture or continues to have low bone mineral
density while on treatment, some clinicians may think that the patient failed therapy, and thus, may
recommend transitioning to another medication.6
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The studies reveal advantages of denosumab because of better patient adherence to the
medication. Patients preferred denosumab therapy compared to bisphosphonate therapy, resulting
in better medication adherence. Thus, denosumab improved bone mineral density over time due to
better compliance of the medication.
Accurate bone mineral density measurements may have been limited by short follow up
periods, especially since denosumab was only given every six months. Several studies only
monitored treatment for one to two years. Some studies included small groups whose participants
were aware that adherence and compliance were being monitored, which may have led to higherthan-expected adherence. Lastly, many of the studies did not have adequate statistical power to
evaluate for fracture prevention.6
The overall goal for treatment of postmenopausal osteoporosis is to reduce the risk of bone
fractures. This goal may be achieved by optimizing treatment and, adherence, continuously
monitoring the efficacy of treatment, and identifying non-responders quickly so that alternative
therapies can be given.4

CONCLUSION
In conclusion, when comparing bisphosphonates to denosumab most of the studies showed
significant improvement in bone mineral density in those patients taking denosumab. These
superior bone mineral density results are most likely due to better compliance. Adherence to
therapy is vital because mineral density is associated with fracture risk. While these research
studies found that denosumab achieved better results, medical practitioners should be cautious
when interpreting these findings because some of those studies were sponsored by pharmacology
companies which could introduce bias. Therefore, additional studies not sponsored by industry
11

are needed to confirm these findings. Furthermore, clinical recommendations can be better
supported with longer-term studies examining fracture rates, and investigations that focus on
compliance and adverse effects as well as efficacy. Lastly, more head-to-head comparisons of
denosumab with bisphosphonates are necessary.
Nonetheless, evidence to date suggests that denosumab is an effective alternative to
bisphosphonates for treating osteoporosis in postmenopausal women. Better patient tolerance of
denosumab may improve compliance. For those patients who have contraindications to oral
bisphosphonates or cannot tolerate their parenteral formulation, denosumab is a valuable option.
The costs of denosumab, however, may be prohibitive.
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